5241642025-04-012025-06-305241642025-06-305241642025-04-012025-06-30in-capmkt:OtherExpenses1Member5241642025-04-012025-06-30in-capmkt:ReportableSegments1Member5241642025-04-012025-06-30in-capmkt:ReportableSegments2Member5241642025-04-012025-06-30in-capmkt:ReportableSegments3Member5241642025-04-012025-06-30in-capmkt:ReportableSegments1Member5241642025-04-012025-06-30in-capmkt:ReportableSegments2Member5241642025-04-012025-06-30in-capmkt:ReportableSegments3Member5241642025-04-012025-06-30in-capmkt:ReportableSegments1Member5241642025-06-30in-capmkt:ReportableSegments1Member5241642025-04-012025-06-30in-capmkt:ReportableSegments2Member5241642025-06-30in-capmkt:ReportableSegments2Member5241642025-04-012025-06-30in-capmkt:ReportableSegments3Member5241642025-06-30in-capmkt:ReportableSegments3Member5241642025-04-012025-06-30in-capmkt:ReportableSegments1Member5241642025-06-30in-capmkt:ReportableSegments1Member5241642025-04-012025-06-30in-capmkt:ReportableSegments2Member5241642025-06-30in-capmkt:ReportableSegments2Member5241642025-04-012025-06-30in-capmkt:ReportableSegments3Member5241642025-06-30in-capmkt:ReportableSegments3Member5241642025-04-012025-06-30ItemsThatWillNotBeReclassifiedToProfitAndLoss15241642025-04-012025-06-30ItemsThatWillBeReclassifiedToProfitAndLoss15241642025-04-012025-06-30AuditorDomain1iso4217:INRiso4217:INRxbrli:shares524164IOLCPNOTLISTINGINE485C01029IOL Chemicals and Pharmaceuticals LimitedMain BoardEquity2025-04-012026-03-312025-08-072025-07-28INRCroresQuarterlyFirst quarterMulti segment2025-08-0713:00:002025-08-0714:20:00Declaration of unmodified opinion2025-04-012025-06-30UnauditedConsolidated551690000073700000559060000037655000000-12320000057650000042300000197700000676700000513550000045510000004551000001049000001090000011580000003393000000000339300000-640000033290000058710000021.161.16001.161.161.The above standalone and consolidated unaudited financial results for the quarter ended 30th June 2025 have been reviewed and recommended to the Board of Directors by the Audit Committee and subsequently approved by the Board of Directors at their meetings held on 7th August 2025. These results have been subjected to limited review by Statutory Auditors who have expressed an unmodified opinion on these results. <BR> <BR> 2.The financial results are prepared in accordance with the Indian Accounting Standards Ind AS prescribed under Section 133 of the Companies Act 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and are in compliance with Regulation 33 of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015. <BR> <BR> 3. As per Ind AS 108 Operating Segments, the Company has two reportable Operating Segments namely Pharmaceuticals and Chemicals. The financial information for these segments has been provided in Financial Results. <BR> <BR> 4. The figures for the quarter ended 31st March 2025, are the balancing figures between the audited figures for the full financial and the unaudited published figures up to 9 months ended 31st December 2024, which were subjected to limited review by the statutory auditors. <BR> <BR> 5. The previous financial period figures have been regrouped/rearranged/restated, wherever considered necessary. <BR> Other676700000Chemical2810600000Pharmaceutical3293300000Unallocated7370000061776000005870000005590600000Chemical59100000Pharmaceutical400900000Unallocated046000000042300000-37400000455100000Chemical5500100000Pharmaceutical14068200000Unallocated479120000024359500000024359500000Chemical2762600000Pharmaceutical1968600000Unallocated2418800000715000000007150000000Items that will not be reclassified to Profir and loss-19000000-19000000-4800000Items that will be reclassified to Profir and loss10400000104000002600000-6400000UnauditedtrueM/s Ashwani & Associatestrue2026-01-31